Plant Name: Corydalis yanhusuo
Taxonomic Information:
Plant ID: NPO827
Plant Latin Name: Corydalis yanhusuo
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
458692
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Analgesic; Antiseptic; Antispasmodic; Antitussive; Cancer; Cardiotonic; Hypotensive; Sedative
Geographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; HTR7; HTR5A; ADRA1A; DRD3; DRD1; DRD2; HTR1A; HTR2B; HTR2A; HTR6; | |
| ACHE; | |
| TDP1; ADK; | |
| CASP3; | |
| CREBBP; | |
| LMNA; F3; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cysteine protease | CASP3 | Caspase-3 | P42574 | CHEMBL2334 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.375E-13 | 2.875E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.375E-13 | 2.875E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 6.805E-13 | 7.799E-10 | ADORA1, ADORA2A, ADRA1A, DRD1, HTR1A, HTR2A, HTR2B, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 5.408E-13 | 7.799E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR7 |
| MF | Unclassified; | GO:0004872; receptor activity | 3.596E-12 | 3.132E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, F3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.081E-11 | 1.462E-08 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 8.959E-10 | 4.877E-07 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.257E-09 | 1.143E-06 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.125E-09 | 2.426E-06 | HTR1A, HTR5A, HTR7 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 6.040E-09 | 2.630E-06 | DRD1, DRD2, DRD3, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.855E-08 | 7.087E-06 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 3.890E-08 | 1.303E-05 | ADORA1, DRD1, DRD2, HTR2A |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 4.475E-08 | 1.412E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 7.154E-08 | 2.105E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.072E-07 | 2.956E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 2.103E-07 | 5.582E-05 | DRD2, DRD3, HTR2B |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 3.640E-07 | 8.907E-05 | ADORA2A, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.640E-07 | 8.907E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 4.630E-07 | 1.084E-04 | ADORA1, DRD2, HTR2A |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.555E-06 | 4.924E-04 | ADRA1A, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 3.712E-06 | 6.572E-04 | DRD2, DRD3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.712E-06 | 6.572E-04 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 4.124E-06 | 6.955E-04 | DRD2, DRD3, HTR2A |
| BP | GO:0008152; metabolic process | GO:0030817; regulation of cAMP biosynthetic process | 4.248E-06 | 6.955E-04 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 4.248E-06 | 6.955E-04 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 8.761E-06 | 1.272E-03 | ADORA1, ADORA2A, ADORA3, ADRA1A, CASP3, DRD2, LMNA |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 9.112E-06 | 1.288E-03 | ADORA1, CASP3, CREBBP, DRD2, LMNA |
| BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 9.814E-06 | 1.349E-03 | ADORA1, ADORA2A, DRD2, HTR1A, HTR2A |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.049E-05 | 1.428E-03 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B, HTR5A, HTR6 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.236E-05 | 1.621E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 1.236E-05 | 1.621E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0042321; negative regulation of circadian sleep/wake cycle, sleep | 1.236E-05 | 1.621E-03 | ADORA1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.236E-05 | 1.621E-03 | HTR2A, HTR2B |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.430E-05 | 1.801E-03 | ADORA1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 1.764E-05 | 2.111E-03 | DRD2, HTR2A, HTR2B |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 1.797E-05 | 2.138E-03 | ADORA1, DRD2, DRD3, HTR2A |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 2.145E-05 | 2.433E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 2.541E-05 | 2.795E-03 | ADORA1, ADORA2A, DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 3.453E-05 | 3.704E-03 | DRD2, DRD3 |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 4.436E-05 | 4.535E-03 | ADORA1, ADORA2A |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.578E-05 | 4.615E-03 | ACHE, ADORA3, CASP3, DRD2 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 4.614E-05 | 4.630E-03 | ADORA1, CREBBP, DRD3, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 5.542E-05 | 5.382E-03 | DRD1, DRD3 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 5.542E-05 | 5.382E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 5.542E-05 | 5.382E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.647E-05 | 6.229E-03 | ADRA1A, DRD2, HTR2A, HTR2B |
| BP | GO:0032501; multicellular organismal process | GO:0007416; synapse assembly | 6.681E-05 | 6.229E-03 | ACHE, DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 6.769E-05 | 6.229E-03 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 6.769E-05 | 6.229E-03 | DRD1, DRD2 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 6.779E-05 | 6.229E-03 | ADORA1, ADORA2A, DRD2, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 8.117E-05 | 7.185E-03 | DRD1, DRD2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 9.586E-05 | 8.283E-03 | ADORA2A, ADRA1A |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 9.586E-05 | 8.283E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0014048; regulation of glutamate secretion | 1.118E-04 | 9.469E-03 | ADORA1, ADORA2A |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.317E-19 | 1.714E-17 | HTR1A, HTR2B, HTR2A, HTR5A, ADRA1A, HTR6, HTR7, ADORA2A, ADORA3, ADORA1, DRD1, DRD2, DRD3 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.247E-13 | 8.316E-12 | HTR6, HTR7, CYP2D6, CASP3, HTR1A, HTR2B, HTR2A, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.057E-11 | 2.608E-10 | HTR6, HTR7, ADORA2A, HTR2B, HTR2A, DRD1, HTR5A, ADRA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.306E-09 | 2.415E-08 | CREBBP, HTR6, ADORA2A, ADORA1, HTR1A, DRD1, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.409E-06 | 3.565E-05 | HTR2B, HTR2A, DRD1, DRD2 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 1.613E-05 | 1.990E-04 | ADORA2A, CASP3, DRD1, DRD2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 3.691E-04 | 3.902E-03 | DRD1, DRD2, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 7.835E-04 | 7.248E-03 | ADORA3, ADORA1, ADRA1A |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 9.578E-04 | 7.876E-03 | ADORA2A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.316E-03 | 9.742E-03 | DRD1, DRD2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2A; HTR2B; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; DRD3; HTR2A; HTR6; HTR1A; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| NA: NA | Episode | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; ACHE; ADORA1; ADORA2A; ADORA3; DRD2; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; ADRA1A; DRD2; HTR1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Social phobia | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; HTR6; HTR1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; ADORA3; CASP3; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; ACHE; ADORA1; DRD1; HTR6; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA1A; ACHE; ADORA2A; DRD1; DRD2; ADK; HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; HTR2A; HTR6; HTR1A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| NA: NA | Addiction | NA | HTR2A; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; DRD2; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| NA: NA | False perceptions | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| NA: NA | Vomiting | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; DRD2; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| NA: NA | Itching | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; DRD3; HTR1A; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; DRD3; HTR1A; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
